2020
Time Since Infection and Risks of Future Disease for Individuals with Mycobacterium tuberculosis Infection in the United States
Menzies NA, Swartwood N, Testa C, Malyuta Y, Hill AN, Marks SM, Cohen T, Salomon JA. Time Since Infection and Risks of Future Disease for Individuals with Mycobacterium tuberculosis Infection in the United States. Epidemiology 2020, 32: 70-78. PMID: 33009253, PMCID: PMC7707158, DOI: 10.1097/ede.0000000000001271.Peer-Reviewed Original ResearchConceptsLatent TB infectionMycobacterium tuberculosis infectionTB infectionTuberculosis infectionTB natural historyRisk of tuberculosisMost TB casesRate of progressionYounger age groupsLower future riskTransmission dynamic modelTB casesTB riskPrevalent infectionProgression riskLifetime riskRisk factorsIncidence trendsClinical diseaseCumulative riskGeneral populationAverage ageNew infectionsUS populationAge groups
2018
The impact of digital health technologies on tuberculosis treatment: a systematic review
Ngwatu B, Nsengiyumva N, Oxlade O, Mappin-Kasirer B, Nguyen N, Jaramillo E, Falzon D, Schwartzman K, Abubakar I, Alipanah N, Bastos M, Boccia D, Chin D, Cohen T, Davis J, Denkinger C, Falzon D, Fielding K, Fox G, Free C, Garfein R, Hayward A, Jaramillo E, Lester R, Lewis J, Mappin-Kasirer B, Marx F, Menzies D, Migliori G, Nahid P, Ngwatu B, Nsengiyumva N, Nguyen N, Oxlade O, Schwartzman K, Siddiqi K, Story A, Thomas B, Trajman A, Yassin M. The impact of digital health technologies on tuberculosis treatment: a systematic review. European Respiratory Journal 2018, 51: 1701596. PMID: 29326332, PMCID: PMC5764088, DOI: 10.1183/13993003.01596-2017.Peer-Reviewed Original ResearchConceptsVideo-observed therapyMedication monitorsStandard careObservational studyTreatment completion ratesTB treatment adherenceProbability of cureTreatment of personsPerson DOTActive tuberculosisTB careClinical outcomesTreatment adherenceTuberculosis treatmentPatient outcomesTreatment completionControl groupTreatment dosesSystematic reviewDigital health technologiesShort message serviceEffect estimatesTuberculosisDigital interventionsCare
2017
Polyclonal Pulmonary Tuberculosis Infections and Risk for Multidrug Resistance, Lima, Peru - Volume 23, Number 11—November 2017 - Emerging Infectious Diseases journal - CDC
Nathavitharana RR, Shi CX, Chindelevitch L, Calderon R, Zhang Z, Galea JT, Contreras C, Yataco R, Lecca L, Becerra MC, Murray MB, Cohen T. Polyclonal Pulmonary Tuberculosis Infections and Risk for Multidrug Resistance, Lima, Peru - Volume 23, Number 11—November 2017 - Emerging Infectious Diseases journal - CDC. Emerging Infectious Diseases 2017, 23: 1887-1890. PMID: 29048297, PMCID: PMC5652442, DOI: 10.3201/eid2311.170077.Peer-Reviewed Original ResearchConceptsTreatment of tuberculosisHost Mycobacterium tuberculosis diversityMultidrug-resistant TBInfectious Diseases journal - CDCPulmonary TB patientsPulmonary tuberculosis infectionTB patientsTuberculosis infectionPolyclonal infectionsSimple infectionMultidrug resistanceInfectionPatientsTuberculosisPrevalenceDiagnosisAntimicrobial Resistance Risks of Cholera Prophylaxis for United Nations Peacekeepers
Kunkel A, Lewnard JA, Pitzer VE, Cohen T. Antimicrobial Resistance Risks of Cholera Prophylaxis for United Nations Peacekeepers. Antimicrobial Agents And Chemotherapy 2017, 61: 10.1128/aac.00026-17. PMID: 28533237, PMCID: PMC5527623, DOI: 10.1128/aac.00026-17.Peer-Reviewed Original ResearchConceptsDrug-resistant infectionsAntimicrobial chemoprophylaxisDrug-sensitive infectionsDrug resistance generationCholera importationChemoprophylaxisDrug resistanceImportation eventsInfectionAntibiotic resistanceAntimicrobial resistance risksRiskRelative benefitsResistance generationCholeraPotential resistance risksPotential benefitsResistance riskProphylaxisPrevalence